Article

Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence

Humboldt-Universität zu Berlin, Berlín, Berlin, Germany
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 09/2004; 89(8):3731-6. DOI: 10.1210/jc.2003-032164
Source: PubMed

ABSTRACT We present a 54-yr-old woman with ectopic corticotropin syndrome caused by a neuroendocrine tumor of the pancreas. At initial presentation, the patient suffered from diarrhea, heartburn, and nonspecific abdominal pain. There was no evidence of Cushing's syndrome. A neuroendocrine tumor in the head of the pancreas with metastases into peripancreatic lymph nodes was diagnosed and completely resected. Fourteen months later, abdominal computed tomography and scintigraphy with (111)In-labeled octreotide suggested relapse of the tumor. The patient again had no evidence of Cushing's syndrome. A second in toto tumor resection was performed. Another 8 months later, the patient developed forgetfulness, depressive episodes, muscle weakness, new-onset hypertension, hypokalemia, plethora, diabetes mellitus, polyuria, and weight loss. Endocrine testing suggested a source of ectopic ACTH production. An octreotide scan showed an intense uptake ventromedial of the left kidney, an area that showed a mass lateral of the superior mesenteric artery on abdominal magnetic resonance imaging. A complete pancreatectomy with splenectomy and left-sided adrenalectomy were performed. At this second relapse, this neuroendocrine tumor clinically had changed its hormonal profile. Immunohistochemically, in contrast to primary tumor and first relapse, we found strong immunostaining for ACTH in tumor cells of the second relapse and a MIB-1 index greater than 20%. To our knowledge, this is the first report describing a pancreatic neuroendocrine tumor that started to secrete ACTH de novo at the time of the second relapse after two former complete tumor resections. This case underscores the pluripotency of neuroendocrine tumor cells and the importance of keeping in mind a possible shift in hormone production during tumor evolution and progression.

Full-text

Available from: Christian A Koch, Dec 22, 2014
0 Followers
 · 
88 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We describe a 71-year-old man who presented with abdominal pain, lower-extremity edema, recent unintentional weight loss, hypertension, hyperglycemia, hypokalemia, and metabolic alkalosis. Serum cortisol levels remained elevated after overnight high-dose dexamethasone suppression. Magnetic resonance imaging revealed a small mass in the head of the pancreas with scattered liver metastases. Both endoscopic ultrasound-guided pancreatic biopsy and liver biopsy revealed a well-differentiated neuroendocrine tumor. These lesions did not show significant uptake on octreotide scan. Medical management and hepatic artery chemoembolization were attempted. Ultimately, the patient underwent bilateral adrenalectomy, but died within 4 months of symptom onset secondary to postoperative complications.
    Proceedings (Baylor University. Medical Center) 01/2015; 28(1):46-9.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: We report the case of a patient who had a non-functional metastatic pancreatic neuroendocrine tumour (pNET), which changed in functionality during the course of the disease. This case demonstrates the effectiveness of conventional cytotoxic chemotherapy in the management of select group of patients with this rare, challenging condition. Case presentation: Our patient was a 34 year old man under oncology follow up, diagnosed with a non-functional metastatic pancreatic neuroendocrine tumour treated with a Whipple's procedure two years ago. Despite treatment with somatostatin analogues and sunitinib, a tyrosine kinase inhibitor, he had demonstrated radiological progression of his metastatic disease. He now presented with a short history of Cushing's syndrome. A presumptive diagnosis of a rapidly progressive, metastatic, functional pNET with ectopic ACTH production was made, confirmed biochemically and with liver biopsy. The proliferative index, Ki-67 of 20% of the liver biopsy prompted us to treat him with conventional cytotoxic chemotherapy using streptozocin, 5-fluorouracil and doxorubicin. Prior to its administration clinical and biochemical control of the hypercortisolemic state was achieved with metyrapone. However the clinical, biochemical and radiological response to chemotherapy was so dramatic obviating the need for metyrapone therapy. Conclusions: Non-functional pNETs may evolve in their clinical and biologic behaviour producing functional hormonal syndromes. Chemotherapy may be an effective therapeutic modality in such circumstances.
    BMC Endocrine Disorders 08/2014; 14(1):70. DOI:10.1186/1472-6823-14-70 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rarely, corticotrophic pituitary tumors take on an aggressive form characterized by rapid growth, invasion into local structures, compression of cranial nerves, and possible spread to distant sites. When conventional surgery, radiation therapy and hormones fail to control progression and symptoms, alternative therapies are needed. A novel chemotherapeutic regimen of capecitabine and temozolomide (CAPTEM), originally designed in our laboratory, demonstrated dramatic anti-neoplastic effects against corticotrophic pituitary tumors. Here we present a case series of four patients with aggressive, ACTH-producing pituitary tumors who had previously depleted all surgical, radiation, and hormonal therapies, and were then treated with CAPTEM. Dramatic clinical improvements in neurological deficits and Cushing's symptoms were evident in all patients after treatment was initiated. Confirmed by radiographic imaging, two of four patients demonstrated complete regression of disease, one patient had a 75% regression, and the fourth patient has ongoing stable disease for over 4.5 years at the time of this writing. Immunohistochemical analysis of patient's tumor samples showed low O-methyguanyl methyltransferase (MGMT) expression and adequate levels of mismatch repair enzymes (MLH-1, MSH-2, MSH-6, and PMS-2), which are important for the in vivo efficacy of CAPTEM. This is the first report of prolonged anti-tumor response and radiographic complete remissions to CAPTEM in patients with aggressive pituitary tumors who had exhausted all other therapies.
    Neurosurgery 11/2013; 74(4). DOI:10.1227/NEU.0000000000000251 · 3.03 Impact Factor